When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MRK - Merck's Latest $2.7-Billion Buy Of ArQule Brings About Precision Targeted And Diversified Approach To Cancer Therapy
Merck & Company Inc.
Merck (MRK) had announced that it would purchaseArQule (ARQL) for a total of $2.7 billion or $20 per share in cash. The main goal for this acquisition was that Merck could add a precision medicine oncology biotech to its portfolio. This acquisition should help the oncology portfolio of Merck, because ArQule has a differentiated approach to treating B-cell malignancies. I believe this was a good acquisition, especially because the lead product of ARQ 531 has been advancing quite well in the clinic. It can be used to treat wild-type and